Value
7.3/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 7.1 |
| Analyst target | 7.5 |
- ▸Attractively valued
NPCE · Why this verdict
Why Neuropace (NPCE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
NPCE has posted a strong recent earnings beat streak, but persistent cash burn, declining revenue, and failed momentum and asymmetry gates keep the quality-driven exit signal in force.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Options positioning shows an elevated put/call ratio of 2.17 alongside high implied volatility of 119%, signaling the options market is pricing in significant downside risk. Risk breakdown | The put/call ratio should fall back toward 1.0 and implied volatility should compress if downside fears are unwarranted. | ↑Improving |
| CounterElevated put/call ratios in small-cap medtech names are often driven by hedging around binary regulatory or reimbursement catalysts rather than a directional bearish view. | ||
The company is cash-burning, with free cash flow at roughly -3% of revenue and a failing Rule of 40 score, reflecting weak fundamental quality. Quality breakdown | Free cash flow margin should turn positive or move meaningfully toward breakeven over the next several quarters if the underlying business is improving. | ↑Improving |
| CounterEarly-stage medical-device companies commercializing a novel therapy commonly run negative free cash flow while scaling adoption, which does not necessarily indicate a failing business model. | ||
Revenue is declining modestly, down about 2%, which weighs against the bullish earnings-beat narrative for this device maker. Growth breakdown | Revenue growth should turn positive, rising above 0% year-over-year, over the next few quarters if adoption is accelerating. | Tripped↑Improving |
| CounterA small revenue decline off a low base can reflect lumpy device-placement timing rather than a durable demand problem, especially for a niche neurostimulation device. | ||
The engine's momentum and asymmetry gates both failed, with momentum at 4.3 versus a 4.5 threshold and an asymmetry ratio of 0.9 versus 1.5, indicating an unfavorable near-term setup. Warnings | Both the momentum score and asymmetry ratio should rise back above their respective thresholds if the setup improves over the next few months. | ↑Improving |
| CounterBoth gate failures are narrow misses (4.3 vs 4.5, 0.9 vs 1.5) that could reverse quickly on a single positive data point rather than reflecting deep structural weakness. | ||
The company has beaten earnings in 3 of its last 4 quarters with an average surprise above 20%, showing recent execution strength. Earnings | The beat rate should stay above 50% over the next several reporting quarters if execution momentum continues. | ↑Improving |
| CounterBeats against deeply negative EPS estimates for a pre-profitability device company can reflect modest cost control rather than a durable improvement in the underlying growth trajectory. | ||
Options positioning shows an elevated put/call ratio of 2.17 alongside high implied volatility of 119%, signaling the options market is pricing in significant downside risk.
↑ImprovingRisk breakdown
- Expectation
- The put/call ratio should fall back toward 1.0 and implied volatility should compress if downside fears are unwarranted.
CounterElevated put/call ratios in small-cap medtech names are often driven by hedging around binary regulatory or reimbursement catalysts rather than a directional bearish view.
The company is cash-burning, with free cash flow at roughly -3% of revenue and a failing Rule of 40 score, reflecting weak fundamental quality.
↑ImprovingQuality breakdown
- Expectation
- Free cash flow margin should turn positive or move meaningfully toward breakeven over the next several quarters if the underlying business is improving.
CounterEarly-stage medical-device companies commercializing a novel therapy commonly run negative free cash flow while scaling adoption, which does not necessarily indicate a failing business model.
Revenue is declining modestly, down about 2%, which weighs against the bullish earnings-beat narrative for this device maker.
Tripped↑ImprovingGrowth breakdown
- Expectation
- Revenue growth should turn positive, rising above 0% year-over-year, over the next few quarters if adoption is accelerating.
CounterA small revenue decline off a low base can reflect lumpy device-placement timing rather than a durable demand problem, especially for a niche neurostimulation device.
The engine's momentum and asymmetry gates both failed, with momentum at 4.3 versus a 4.5 threshold and an asymmetry ratio of 0.9 versus 1.5, indicating an unfavorable near-term setup.
↑ImprovingWarnings
- Expectation
- Both the momentum score and asymmetry ratio should rise back above their respective thresholds if the setup improves over the next few months.
CounterBoth gate failures are narrow misses (4.3 vs 4.5, 0.9 vs 1.5) that could reverse quickly on a single positive data point rather than reflecting deep structural weakness.
The company has beaten earnings in 3 of its last 4 quarters with an average surprise above 20%, showing recent execution strength.
↑ImprovingEarnings
- Expectation
- The beat rate should stay above 50% over the next several reporting quarters if execution momentum continues.
CounterBeats against deeply negative EPS estimates for a pre-profitability device company can reflect modest cost control rather than a durable improvement in the underlying growth trajectory.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.1 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -2% of revenue
- ▸Rule of 40: 15 (fail)
Growth
6.8/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 6.8 |
Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 8.5 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 0.8 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+4.9%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.9 |
| Analyst rating | 8.0 |
| Price target | 9.0 |
- ▸LLM news sentiment: +0.38 (n=2)
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 37%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.9 |
| quality rank | 1.1 |
| growth rank | 7.1 |
Technical
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.1 |
| support resistance | 4.3 |
| 52w position | 5.1 |
Risk (lower is worse)
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.6 |
| days to cover | 6.2 |
| volatility | 0.0 |
| put call | 2.5 |
| beta | 3.5 |
| debt equity | 0.0 |
- ▸Elevated put/call: 1.63
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:5.8>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:79d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (0)
none
Reward-to-Risk
1.34
Upside
+19.1%
Downside
14.3%
Sizing output
AVOID
SetupRange Bound — RSI 46 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilityAggressive — Beta 1.94>1.3, MCap $0.5B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's 1.3<1.5@spot outcome against Sentiment at 8.0 and asymmetric R:R of 1.34.
The strongest dimensions are Sentiment at 8.0, Value at 7.3, and Insider at 7.3; the weakest are Peer rank at 2.8, Quality at 3.1, and Risk (lower is worse) at 3.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.34 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burning Weak Quality
Trip ifFree cash flow margin rises above 5% of revenue from the current -3%, reversing the cash-burn quality concern.
- P2Declining Revenue TrendTripped
Trip ifRevenue growth rises above 0% YoY from the current -2% decline, turning positive.
- P3Failed Momentum Asymmetry Gates
Trip ifMomentum score rises above 4.5 and asymmetry ratio rises above 1.5, clearing both currently failed gates now at 4.3 and 0.9 respectively.
- P4Elevated Put Call Risk
Trip ifPut/call ratio falls below 1.0 from the current 2.17, easing the elevated options risk skew.
- P5Recent Earnings Beat Strength
Trip ifQuarterly EPS beat rate falls below 50% over the next 4 quarters, reversing the current 3-of-4 beat streak.